Fact-checked by Grok 2 weeks ago

Left ventricular thrombus

Left ventricular thrombus (LVT) is a blood clot that forms within the left ventricle of the heart, typically as a complication of acute (MI) or nonischemic cardiomyopathies such as . It arises due to in areas of impaired ventricular wall motion, endocardial injury, and a hypercoagulable state, aligning with , and is characterized by thrombi that may be protuberant and mobile in the acute phase or mural and sessile in chronic cases. LVT significantly increases the risk of systemic , including , and is linked to higher rates of cardiovascular events and mortality, with an overall incidence ranging from 2.7% to 15% following ST-elevation MI (STEMI), particularly in anterior wall involvement. The primary causes of LVT include anterior STEMI, where apical akinesis or dyskinesis promotes thrombus formation, often in the context of reduced left ventricular (LVEF <40%) and delayed reperfusion. Other risk factors encompass large infarct size, severe diastolic dysfunction, inflammation, and hypercoagulability post-MI, as well as nonischemic conditions like or . In patients with , the incidence varies from 2% to 36%, driven by chronic ventricular dilation and stasis. Prophylactic measures, such as early anticoagulation in high-risk post-MI cases, are considered per guidelines, though the overall incidence has declined with advances in . Diagnosis of LVT relies on , with transthoracic () enhanced by agents serving as the first-line modality, offering up to 100% and specificity of 99% when optimized. Cardiac magnetic resonance (CMR) provides superior accuracy for detecting small or mural thrombi, with of 82-88% and specificity approaching 100%, and is recommended for equivocal cases. Transesophageal () may be used in select scenarios but is less routine due to invasiveness. Early detection within 1-2 weeks post-MI is crucial to mitigate embolic risks. Management focuses on anticoagulation to prevent and promote resolution, with antagonists (VKAs) like recommended for at least 3 months (target international normalized ratio 2.0-3.0), supported by Class IIa evidence in guidelines. Direct oral anticoagulants (DOACs), such as , are reasonable alternatives, particularly for patients intolerant to VKAs, with recent randomized trial data (as of 2025) showing similar efficacy to VKAs. Surgical is reserved for rare cases of large, mobile thrombi refractory to medical therapy. Follow-up imaging assesses resolution, with persistent LVT warranting extended anticoagulation. Prognosis for LVT remains guarded, with embolic events occurring in 16-22% of untreated cases and overall mortality elevated compared to MI without thrombus, with increased risk of . Thrombus resolution, achieved in most patients with anticoagulation, correlates with improved outcomes, though residual risk of and cardiovascular death persists even after resolution. Ongoing trials are evaluating optimal DOAC regimens to refine therapeutic strategies.

Overview

Definition

A left ventricular thrombus (LVT) is a blood clot that forms within the left ventricle of the heart, typically adhering to the endocardial surface in regions of impaired myocardial contractility, such as akinetic or dyskinetic segments of the ventricular wall. This thrombus develops due to the stagnation of blood flow in areas of reduced ventricular motion, often at the apex, and is distinct from clots in other cardiac chambers by its association with left ventricular systolic dysfunction. Unlike thrombi in the right ventricle or atria, LVT is predominantly linked to conditions causing significant impairment in left ventricular ejection fraction, leading to localized blood stasis. The composition of LVT primarily consists of fibrin strands, platelets, trapped red blood cells, and other cellular elements, forming a layered structure influenced by of stasis, endothelial injury, and hypercoagulability. It is usually mural, meaning it remains attached to the ventricular wall, but can become mobile or pedunculated, protruding into the ventricular cavity and increasing the risk of . This adherent or protruding nature underscores its potential for systemic complications, though its formation is most commonly precipitated by acute affecting the anterior wall.

Epidemiology

Left ventricular thrombus (LVT) occurs in approximately 5-10% of patients with acute anterior ST-segment elevation (STEMI) in the contemporary era of . In patients with left ventricular aneurysms following , the incidence is higher in historical cohorts without early intervention, with risks of thrombus or related embolic events reported up to 24% over follow-up in modern studies. By contrast, the incidence is lower in , estimated at 2-36%, with higher rates in advanced cases with severe systolic dysfunction detected by optimal imaging. Advanced imaging such as cardiac magnetic resonance (CMR) reveals higher incidences, up to 12-27% in anterior STEMI, compared to 5-15% with transthoracic . Prevalence of LVT is approximately 0.5-1% in general populations, but it rises significantly in post-acute cohorts, reaching up to 15% in untreated anterior wall infarctions. Demographically, LVT is more common in males, predominantly affecting older adults over 60 years and those with comorbidities like diabetes mellitus. The condition's incidence has declined markedly due to widespread adoption of reperfusion therapies, dropping from up to 40-60% in the pre-reperfusion era to 2.7-9% in the contemporary period. Globally, LVT incidence is higher in low-resource settings where delayed treatment limits timely reperfusion, leading to greater rates of formation compared to high-resource environments. As of 2024, epidemiological data indicate stable overall rates, though increased detection has been noted with the routine use of advanced imaging modalities like cardiac magnetic resonance. The presence of LVT is linked to elevated mortality, with an overall 20-30% one-year mortality rate, primarily driven by cardiovascular events.

Causes and Risk Factors

Underlying Conditions

Left ventricular thrombus (LVT) most commonly arises in the context of acute (AMI), particularly involving the anterior wall, where apical akinesia or disrupts blood flow patterns. In patients with ST-elevation (STEMI), the incidence of LVT is estimated at 5% to 15% when assessed by transthoracic , with higher rates (up to 12.7%) observed in anterior STEMI cases due to the resulting ventricular dysfunction. Recent analyses report a post-STEMI LVT incidence of approximately 5-6% in contemporary cohorts, reflecting improvements in but persistent risk in severe cases. Heart failure and various cardiomyopathies represent another major group of underlying conditions, characterized by reduced left ventricular (LVEF) and chamber dilatation that promote formation. The incidence of LVT among patients with (typically defined by LVEF below 35-40%) ranges from 2% to 36%, with accounting for approximately 8% of overall LVT cases, driven by global hypokinesis leading to stagnant flow. Ischemic cardiomyopathy, stemming from prior , is the predominant etiology, comprising up to 80% of LVT occurrences in affected patients. Non-ischemic forms, such as those triggered by viral , further elevate risk through inflammatory damage and systolic impairment. Other non-ischemic conditions include Chagas cardiomyopathy (with LVT risk up to 39% in aneurysmal cases), (5-15% incidence), and . Post-infarction left ventricular aneurysm formation exacerbates LVT susceptibility by creating dyskinetic segments that impair ventricular emptying. These aneurysms typically develop from adverse remodeling after AMI, particularly in untreated or delayed reperfusion scenarios. Additional cardiac conditions include , where transient apical ballooning induces LVT in 1.3% to 7.7% of cases, often within the first 48 hours. Atrial fibrillation frequently coexists as a complicating factor, present in about 17% of anterior STEMI patients with LVT, where it amplifies stasis through irregular ventricular filling.

Predisposing Factors

Low ejection fraction (LVEF <40%) is the strongest predictor of left ventricular thrombus (LVT) formation, particularly in post-myocardial infarction (MI) patients, with studies reporting odds ratios ranging from 3.35 to 13.7 depending on the severity of systolic dysfunction. Demographic factors also contribute to increased susceptibility; male sex is associated with higher overall MI complication rates, including LVT, due to greater prevalence of coronary artery disease. Advanced age greater than 65 years elevates risk through compounded cardiovascular vulnerabilities, while African American ethnicity correlates with higher LVT incidence, potentially linked to disparities in MI severity and access to timely care. Comorbidities further modify LVT susceptibility by promoting a prothrombotic . Diabetes mellitus impairs endothelial function and accelerates , independently raising LVT risk in patients with underlying cardiac conditions. induces a hypercoagulable state via endothelial damage and platelet activation, with higher prevalence noted in LVT cases. contributes through chronic and altered , exacerbating and stasis. Procedural factors during acute management significantly influence LVT development. Delayed reperfusion beyond 12 hours from symptom onset heightens the risk by allowing prolonged ischemia and akinesis in the left ventricle. Similarly, the absence of dual antiplatelet therapy post- fails to adequately mitigate thrombotic tendencies, increasing LVT formation compared to standard regimens. Laboratory markers provide additional prognostic value for risk stratification. Elevated levels exceeding 444 ng/mL serve as an independent predictor of LVT, reflecting underlying fibrinolytic activity and clot burden. Recent studies have linked higher peak levels to early LVT detection, indicating greater myocardial necrosis and associated hypercoagulability. Genetic predispositions, though rare, play a role in non-ischemic LVT cases. Prothrombotic mutations such as can precipitate thrombus formation in the setting of ventricular dysfunction without overt ischemia, by impairing natural anticoagulation pathways.

Pathophysiology

Blood Stasis

Blood stasis represents the hemodynamic component of that plays a pivotal role in left ventricular thrombus (LVT) formation, particularly in the setting of impaired ventricular contractility. Following acute (MI), especially anterior wall involvement, reduced left ventricular and regional wall motion abnormalities lead to diminished blood flow velocities within the chamber. This sluggish circulation fosters an environment conducive to platelet activation and aggregation, initiating thrombus development at sites of flow stagnation. The mechanism is prominently driven by akinetic or dyskinetic myocardial segments, such as those in the apical region post-anterior , where contractile dysfunction creates low-shear zones. These areas exhibit prolonged blood residence times, quantified through higher values of the echocardiographic wall motion score index (WMSI), which indicate extensive hypokinesis or akinesis and correlate with heightened LVT risk by promoting localized . As the primary initiator within for many post- cases, this stagnation disrupts normal , allowing erythrocytes and platelets to accumulate and form the nidus for clot propagation. Specific to LVT, thrombi predominantly form at the due to the ventricle's conical , which inherently results in slower flow patterns and recirculation in this distal region during and . Smoke-like spontaneous echocardiographic contrast, arising from formation in these low-velocity zones, further signals the degree of and predisposes to adherence. This hemodynamic predisposition is often exacerbated by concurrent endothelial damage from the ischemic insult.

Endothelial Injury

Endothelial injury represents a critical component of in the pathogenesis of left ventricular thrombus (LVT), particularly following acute (MI), where ischemic damage to the endocardial surface disrupts its antithrombotic properties. Ischemic injury exposes subendothelial , which binds (vWF), thereby facilitating platelet adhesion and activation through glycoprotein Ibα interactions, initiating thrombus formation on the ventricular wall. Inflammatory processes exacerbate this injury, with cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) released during contributing to endothelial erosion and dysfunction. These cytokines promote a prothrombotic environment by upregulating adhesion molecules and impairing endothelial integrity, creating a nidus for deposition and further platelet recruitment. In the of LVT, endothelial is often localized to areas of aneurysmal thinning or fibrotic post-MI, where the thinned, akinetic myocardium lacks functional , enhancing . Recent 2025 imaging studies utilizing late enhancement on cardiac magnetic resonance have demonstrated that areas of uptake, indicative of myocardial and , strongly correlate with sites of LVT formation, highlighting the spatial link between endocardial damage and localization. Thrombus progression begins with microthrombi adhering to the injured endocardial surface, evolving into multilayered clots through iterative platelet aggregation and stabilization. In non-stasis regions of the left ventricle, modulates this growth by influencing vWF unfolding and platelet tethering, potentially accelerating layering in moderately flowing areas adjacent to akinetic segments. This endothelial injury synergizes with in apical regions to promote LVT development.

Hypercoagulability

Hypercoagulability represents a key component of in the of left ventricular thrombus (LVT), characterized by an imbalance in the hemostatic system that favors clot formation. Following acute (MI), the acute phase response triggers elevations in procoagulant factors, including fibrinogen, , and (PAI-1). These changes enhance thrombin generation and impair , thereby promoting thrombus development within the left ventricle. Local activation of the coagulation cascade further amplifies this prothrombotic state, with released from damaged myocytes initiating the extrinsic pathway and leading to deposition. Platelets contribute substantially to LVT formation, accumulating in the infarcted region and supporting stability in the majority of cases. Recent studies have identified elevated thrombin-antithrombin (TAT) complexes in LVT patients, reflecting heightened activity and ongoing . In , dehydration exacerbates this by causing hemoconcentration of clotting factors, which intensifies the risk of initiation. Chronic conditions such as (AFib) or introduce a systemic hypercoagulable milieu that predisposes to LVT, with AFib linked to increased coagulation factor levels and malignancy inducing widespread prothrombotic alterations. This biochemical predisposition synergizes with and endothelial injury to facilitate LVT in vulnerable patients.

Clinical Features

Presentation

Left ventricular thrombus (LVT) is often asymptomatic, with the majority of cases detected incidentally during routine transthoracic echocardiography in patients recovering from acute (AMI). Patients typically do not experience symptoms directly attributable to the thrombus itself, as it forms silently within the left ventricle due to regional wall motion abnormalities. Any presenting symptoms are usually related to the underlying condition, such as AMI or , and may include dyspnea, , or . In the context of AMI, these manifestations align with the acute coronary event rather than the . Premonitory signs of potential can include transient ischemic attacks or vague neurological symptoms, which may precede more severe embolic events. Additionally, isolated case reports describe arising from microemboli leading to in the absence of other abdominal pathology. LVT formation typically peaks 1 to 2 weeks following AMI, coinciding with the period of maximal akinesis in the infarcted region. In patients with chronic , thrombi may develop later, often months after the onset of ventricular dysfunction.

Detection

Left ventricular thrombus (LVT) is frequently detected incidentally during routine imaging performed in the aftermath of an anterior (MI), particularly through (TTE) conducted between days 3 and 7 post-event, when the risk of thrombus formation peaks due to regional wall motion abnormalities. This timing aligns with standard protocols for assessing left ventricular (LV) function in patients with ST-elevation MI (STEMI), where before hospital discharge is recommended to identify complications such as reduced or . In patients with low LV (LVEF <40%), routine screening via TTE is similarly employed to evaluate systolic dysfunction and uncover subclinical thrombi, as these individuals exhibit heightened stasis in the LV apex. Screening becomes mandatory in high-risk scenarios, including the presence of aneurysm or severe regional wall motion abnormalities (RWMA), where the incidence of LVT can reach 15-20% in the first two weeks post-MI. The 2025 ACC/AHA guidelines for acute coronary syndromes endorse as the primary modality for assessment in all STEMI patients prior to , facilitating incidental detection of LVT amid evaluations for overall cardiac recovery. For those with anterior STEMI and apical akinesis or dyskinesis, follow-up at 1-2 weeks is advised if initial imaging is negative, given the elevated risk during this period. Clinical suspicion often triggers targeted searches for LVT, such as in cases of unexplained systemic or progressive symptoms, where is pursued to rule out embolic sources. Detection challenges arise particularly with small thrombi (<1 cm in diameter) or those located in the LV apex, which may be obscured by trabeculae or near-field artifacts on standard , complicating differentiation between mobile (protruding) and mural (flat, adherent) forms. Up to two-thirds of LVT may be missed on initial non-contrast , underscoring the need for follow-up in at-risk patients to confirm resolution or emergence of thrombi.

Diagnosis

Imaging Modalities

Transthoracic echocardiography (TTE) serves as the first-line imaging modality for detecting left ventricular thrombus (LVT) due to its non-invasive nature, widespread availability, and real-time visualization capabilities. It employs two-dimensional and Doppler to identify thrombi as echodense masses distinct from the myocardium, particularly effective for apical thrombi with reported of 25-39% without and 39-88% with , and specificity of 81-99%. In patients with poor acoustic windows, such as those with or , agents like Definity (perflutren lipid microspheres) enhance endocardial border definition and improve diagnostic accuracy by opacifying the left ventricular cavity. Per the 2022 scientific statement, is recommended as the initial imaging test, with contrast advised for suboptimal endocardial definition to reduce false negatives; if results are equivocal or clinical suspicion remains high (e.g., embolic event), advanced imaging such as cardiac magnetic resonance is indicated. Transesophageal () is generally not recommended for LVT detection due to poor visualization of the left ventricular apex, the most common site of thrombus formation, despite its higher resolution for other cardiac structures. Cardiac magnetic resonance imaging (CMR) is considered the gold standard for confirming LVT in equivocal cases, leveraging sequences like cine and late gadolinium enhancement to differentiate as a hypointense avascular mass from viable myocardium or tumors. Validation studies report of 88% and specificity of 99-100%. Cardiac computed tomography (CT) provides a viable alternative for patients with contraindications to CMR, such as implanted devices, using delayed-phase or protocols to identify filling defects consistent with and distinguish them from pseudomasses or tumors via contrast washout patterns. Gated protocols minimize motion artifacts and radiation exposure while maintaining high diagnostic yield. Multimodal imaging approaches integrate with or when initial is inconclusive, as endorsed by the 2022 scientific statement, which emphasizes advanced modalities for high-risk cases to balance diagnostic precision against considerations like in and risks in .

Diagnostic Criteria

Diagnosis of left ventricular () primarily relies on modalities such as transthoracic (), which identifies a as an echodense mass within the left ventricular , distinct from the , and adjacent to a region of hypokinetic or akinetic myocardium. The mass must exhibit margins separate from surrounding structures, such as papillary muscles or , and demonstrate independent motion relative to the ventricular wall to confirm its presence and exclude artifacts. Thrombi smaller than 5 mm are often challenging to distinguish from normal variants or artifacts and may require confirmatory advanced . The size, shape, and mobility of the LVT further inform diagnostic confidence and . Protruding or mobile thrombi, often described as pedunculated or ball-like, are more readily identifiable on due to their distinct excursion from the wall and carry a higher embolic compared to flat, layered mural thrombi. Layered thrombi, which adhere closely to the endocardial surface, may appear subtler and necessitate contrast enhancement for delineation. Advanced imaging techniques provide higher specificity when echocardiography is equivocal. Cardiac magnetic resonance (CMR) characterizes LVT as an avascular mass within the left ventricular cavity, exhibiting no late gadolinium enhancement and distinct borders from the myocardium on cine and perfusion sequences. On , LVT typically presents as a low-attenuation filling defect with mean Hounsfield units (HU) of approximately 43 (range 25-80 HU), helping differentiate it from pseudomasses caused by incomplete contrast mixing. Diagnostic challenges include differentiation from pseudothrombi, particularly in conditions like apical , where hypertrophied myocardium can mimic thrombus appearance on . Interobserver variability remains a limitation, especially with , though CMR reduces this variability compared to alone.

Treatment

Anticoagulation

Anticoagulation remains the cornerstone of pharmacological management for left ventricular (LVT), aimed at promoting resolution while minimizing embolic and bleeding risks. Vitamin K antagonists, particularly , are considered the first-line therapy according to the 2022 scientific statement, with a target international normalized ratio (INR) of 2.0 to 3.0 to achieve therapeutic anticoagulation. This regimen has demonstrated high resolution rates, exceeding 95% at 3 months in recent randomized controlled trials, reflecting its established efficacy in preventing progression. Direct oral anticoagulants (DOACs), such as and , are increasingly used off-label for LVT due to their convenience and favorable safety profile, though they lack formal approval for this indication from regulatory bodies like the FDA. The 2025 RIVAWAR trial, a single-center randomized study of patients with post-myocardial LVT, found (20 mg daily) to be non-inferior to , with complete thrombus resolution exceeding 95% in both arms at 3 months and no significant difference in major bleeding events. Similarly, (5 mg twice daily) has shown comparable resolution rates to in smaller trials, with relative success of 95% at 3 months. The recommended duration of anticoagulation is typically 3 to 6 months, with extension beyond this period if serial imaging confirms persistent LVT; cessation may occur upon documented resolution to balance thrombotic and hemorrhagic risks. In acute cases, particularly with recent , initial bridging with unfractionated or is advised until therapeutic levels of oral agents are achieved, often within the first 48-72 hours. Monitoring involves serial at 1- to 3-month intervals to assess resolution, alongside regular evaluation of bleeding risk using tools like the score, which stratifies patients for major hemorrhage probability (e.g., scores ≥3 indicate high risk warranting closer surveillance). For , frequent INR testing (initially weekly, then monthly once stable) is essential to maintain the target range. In patients with LVT complicating recent , anticoagulation is often combined with dual antiplatelet therapy (e.g., aspirin plus a inhibitor) for the initial period, transitioning to single antiplatelet therapy after 3-6 months as per guideline-directed medical therapy. A 2024 showed a similar LVT resolution rate (OR 1.08) but reduced events (OR 0.70) with DOACs compared to .

Surgical Options

Surgical options for left ventricular thrombus (LVT) are reserved for cases where anticoagulation fails or is contraindicated, particularly in patients with high embolic risk. Indications include large mobile thrombi exceeding 2 cm in diameter, evidence of despite optimal medical therapy, or concurrent surgical needs such as coronary artery bypass grafting (CABG) or repair. Thrombectomy involves direct surgical removal of the , typically performed via open-heart surgery during concomitant procedures like CABG to minimize additional risk. This approach achieves removal success rates exceeding 90% in selected patients, though ranges from 5% to 10%, influenced by underlying left ventricular dysfunction and comorbidities. In the presence of associated left ventricular aneurysm, aneurysm repair incorporates thrombus extraction using techniques like the Dor procedure, which employs an endoventricular circular patch plasty to restore ventricular geometry and exclude the aneurysmal segment. This method demonstrates favorable long-term outcomes, with studies reporting reduced thrombus recurrence rates to below 10% at follow-up and improved survival compared to medical management alone; recent analyses up to 2024 confirm sustained benefits in reducing embolic events post-procedure. Endovascular approaches, such as catheter-based mechanical aspiration, represent rare alternatives for removal, primarily in high-risk surgical candidates with accessible apical thrombi. These minimally invasive techniques show technical success in case series but lack robust randomized evidence, with limited adoption due to procedural complexity and potential for incomplete extraction. Contraindications to surgical intervention include elevated operative risk, such as EuroSCORE II values greater than 10, where prolonged anticoagulation is preferred over invasive therapy to avoid excessive morbidity.

Prevention

Post-MI Strategies

Following a (MI), preventive strategies for left ventricular thrombus (LVT) focus on early detection, risk stratification, and optimization of therapies to mitigate akinesis and remodeling in the acute phase. Screening with transthoracic (TTE), preferably with contrast enhancement, is recommended for high-risk patients with ST-elevation MI (STEMI), such as those with anterior wall involvement or left ventricular (LVEF) <40%, performed between days 3 and 7 post-event to identify subclinical thrombi during the peak risk period. This approach is supported by guidelines emphasizing its role in high-risk subsets, where apical akinesia is common. All patients receive dual antiplatelet therapy as the foundation, typically aspirin combined with a inhibitor such as clopidogrel, to address coronary patency while balancing risks. For high-risk patients—defined by left ventricular (LVEF) less than 40%, anterior , or ventricular aneurysm—early prophylactic anticoagulation is considered in addition to antiplatelet therapy. The 2022 American Heart Association () scientific statement suggests considering antagonists like or direct oral anticoagulants (DOACs) for 1 to 3 months on a case-by-case basis in these high-risk cases, as the risk of LVT formation peaks early post- and resolves with ventricular recovery. This strategy aims to prevent in akinetic segments without routine use in lower-risk patients, where evidence for benefit is limited. Optimizing reperfusion through timely () is a cornerstone, as primary has reduced LVT incidence by approximately 50% compared to historical thrombolytic or eras, primarily by preserving myocardial viability and minimizing akinesis. Delays in exceeding 6 hours from symptom onset significantly heighten remodeling and thrombus risk, underscoring the need for times under 90 minutes per guidelines. Lifestyle interventions complement pharmacological measures by targeting adverse remodeling. is critical, as continued tobacco use exacerbates and promotes prothrombotic states post-MI. Strict control, aiming for less than 130/80 mmHg through diet and medications, reduces wall stress and , thereby lowering LVT predisposition. These modifiable factors, integrated into secondary prevention programs, enhance long-term ventricular . As of 2025, updates from cardiovascular imaging societies advocate routine cardiac magnetic resonance (CMR) in equivocal cases to refine and guide anticoagulation initiation, given CMR's superior sensitivity (up to 88%) for detecting mural thrombi in post-MI settings with indeterminate echoes. This targeted use helps avoid unnecessary therapy while ensuring precise management in complex recoveries.

High-Risk Management

In patients with chronic and reduced (HFrEF), particularly those with non-ischemic (DCM), optimizing medical therapy is essential to improve left ventricular function and mitigate the risk of left ventricular (LVT) formation. Beta-blockers, such as or metoprolol succinate, and inhibitors (ACEi), like enalapril, are cornerstone therapies that enhance (EF) by reducing neurohormonal activation and remodeling, thereby decreasing in the left ventricle. For ongoing monitoring, is recommended as clinically indicated, such as every 6-12 months in stable patients with EF below 35% or upon symptoms, to assess for thrombus development or worsening systolic function. Device-based interventions play a key role in high-risk management for those with ventricular dyssynchrony. Implantable cardioverter-defibrillators (ICD) and (CRT) devices are indicated in HFrEF patients with EF ≤35% and prolonged QRS duration, as they synchronize ventricular contraction, improve EF, and reduce the arrhythmic substrate that contributes to LVT risk. If (AFib) coexists, which is common in up to 30% of HFrEF cases and heightens thromboembolic potential, anticoagulation with a direct oral anticoagulant (DOAC) or is mandated alongside device therapy to address the combined risks. Controlling comorbidities is critical to stabilize cardiac and prevent LVT in chronic settings. In patients with , rigorous glycemic management targeting HbA1c below 7% reduces microvascular damage and HF progression, indirectly lowering thrombus risk through better endothelial function. therapy, such as at 20-40 mg daily, promotes plaque stabilization in underlying coronary disease and improves left ventricular systolic function in , decreasing ischemic triggers for thrombus. For antithrombotic prophylaxis in select cases of non-ischemic without overt LVT but with persistent low EF and additional risk factors, anticoagulation may be considered on an individualized basis per guidelines, though routine use is not recommended. The 2023 ESC guidelines for acute and chronic , updated in 2024 implementations, endorse individualized anticoagulation in non-ischemic with additional risk factors (e.g., AFib or prior ), typically for 3-6 months with repeat imaging to guide duration. As of 2025, ongoing trials such as the Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior (NCT06742567) are assessing the role of low-dose DOACs in preventing LVT in high-risk patients without thrombus. Patient education empowers high-risk individuals to recognize early warning signs of LVT or HF . Instructions should emphasize monitoring for symptoms such as sudden dyspnea, , or neurological changes suggestive of , with prompt reporting to healthcare providers for evaluation, including urgent . This approach fosters adherence to therapy and facilitates early detection, potentially averting severe outcomes.

Complications and Prognosis

Embolic Risks

One of the primary complications of left ventricular thrombus (LVT) is systemic , where fragments of the dislodge and travel through the arterial circulation, potentially causing ischemic events in distant organs. This risk is particularly elevated in the early post-formation period, with untreated LVT carrying an annual or systemic rate of approximately 10% to 15%. Stroke represents the most common embolic consequence of LVT, occurring via occlusion of and leading to ischemic infarcts. The annual risk is estimated at 10-15% in untreated cases, with higher rates observed in patients with mobile thrombi, which are more prone to dislodgement. Mobile thrombi can be detected through advanced imaging modalities such as or cardiac magnetic resonance, aiding in risk stratification. Peripheral embolism from LVT can manifest as limb ischemia, resulting in acute , , and potential loss requiring . Other sites include mesenteric , presenting with severe due to bowel ischemia, as well as renal and splenic involvement leading to organ . Coronary is a rarer event but can provoke acute by occluding . Key predictors of include a protruding shape and mobility of the , which increase the likelihood of dislodgement compared to sessile forms, as well as size greater than 10 mm. Lack of anticoagulation further heightens this risk. The overall incidence of is approximately 10-15% per year in untreated LVT, though this drops to less than 2% annually with appropriate antithrombotic therapy.

Outcomes

Patients with left ventricular thrombus (LVT) face a 1-year all-cause mortality rate of approximately 13-18%, primarily driven by underlying cardiovascular disease such as systolic dysfunction and myocardial infarction, with cardiovascular causes accounting for nearly 90% of deaths. The presence of LVT independently elevates mortality risk by about 10%, as evidenced by higher death rates (25%) in unresolved cases compared to resolved thrombi (15.2%). Recurrence of LVT occurs in 8-14% of cases following cessation, with rates rising to over 20% in patients with persistent low (LVEF ≤50%) or left . Recurrence is associated with poorer prognosis, including increased (). The 5-year MACE rate, encompassing stroke and myocardial infarction, approaches 37-40% in LVT patients, though extension of anticoagulation beyond 3 months—particularly in those with LVEF ≥35%—significantly reduces these events per American Heart Association guidelines. Recent prognostic models, validated in 2025 studies such as Leow et al., incorporate LVEF and thrombus size to predict mortality, with low LVEF (≤50%) and larger thrombus area independently raising risk. A 2025 cluster analysis identified two phenotypes: younger patients post-acute myocardial infarction with better outcomes versus older patients with ischemic cardiomyopathy and higher mortality risk (HR 2.27). Key prognostic factors include early detection and thrombus resolution, which substantially lower embolic risk compared to persistent thrombi, alongside improved outcomes with direct oral anticoagulants (DOACs) due to superior adherence and reduced stroke/mortality rates (odds ratios 0.71 and 0.60 versus vitamin K antagonists).

References

  1. [1]
    Management of Patients at Risk for and With Left Ventricular Thrombus
    After anterior wall MI, reduced LVEF is a significant risk factor for thrombus formation, and most thrombi occur in the area of apical wall motion abnormalities ...
  2. [2]
    Left Ventricular Thrombus Following Acute Myocardial Infarction
    LV thrombi can be classified as protuberant and/or mobile when acute or mural and/or sessile and flat in the chronic period (Figure 1) post-MI. TTE has high ...
  3. [3]
    Management of left ventricular thrombus: a narrative review - PMC
    LVT is associated with increased risk of systemic embolism, stroke, cardiovascular events and death, and there is evidence that anticoagulant therapy for at ...
  4. [4]
    Left ventricular thrombus - UpToDate
    Aug 12, 2025 · INTRODUCTION. Thrombus in the heart chambers can lead to embolic stroke, systemic embolic events, or pulmonary embolism.Missing: definition anatomy
  5. [5]
    Left Ventricular Thrombus: Contemporary Etiologies, Treatment ...
    Mar 4, 2019 · Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality.Missing: definition | Show results with:definition
  6. [6]
    Incidence of left ventricular thrombus following STEMI in the modern ...
    Mar 29, 2024 · Our analysis reveals a 5.6 % rate of LVT across all-territory STEMI, escalating to 12.7 % in anterior STEMI. The higher incidence of LVT in ...
  7. [7]
    Retrospective Analysis of Left Ventricular Thrombus Among Heart ...
    Nov 1, 2022 · Hypertension, hypothyroidism, and atrial fibrillation were found to be the commonest associated risk factors of LVT, 45%, 12.5%, and 30% ...
  8. [8]
    Emerging Trends in Left Ventricular Thrombus - NIH
    Apr 30, 2024 · The meta-analysis reported an overall LVT incidence of 6.3%, with 96% occurring in the context of anterior ST-segment elevation myocardial ...
  9. [9]
    Severe Left Ventricular Thrombus in the Context of Heart Failure and ...
    A peak mortality rate of 27.9% for LVT has been reported, especially among patients with severe LV systolic dysfunction. Poor hemodynamics and blood stasis ...<|control11|><|separator|>
  10. [10]
    2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the ...
    The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes incorporates new evidence since the 2013 ACCF/AHA ...
  11. [11]
    Risk factors for left ventricular thrombus formation on transthoracic ...
    Oct 14, 2021 · The specific risk factors for left ventricular thrombus (LVT) formation on transthoracic echocardiography (TTE) independent of age, sex, and ...Missing: predisposing | Show results with:predisposing
  12. [12]
    Left Ventricular Thrombus in Myocardial Infarction After Successful ...
    The lower the LVEF, the higher the risk: Odds ratios (ORs) were 7.1 and 13.7 for moderate and severe LV systolic dysfunction, respectively (P < 0.0001).
  13. [13]
    Massive Left Ventricular Thrombus After ST-Segment Elevation ...
    An increasing proportion of ACSs occur among young adults (<55 years of age). These patients have similar risk factors as older adults, including male sex, high ...<|control11|><|separator|>
  14. [14]
    Clinical profile and prognosis of elderly patients with left ventricular ...
    Jul 10, 2023 · Among elderly individual, left ventricular thrombus (LVT) is associated with a higher risk of cardiovascular events and death [1, 2].
  15. [15]
    Risk factors and outcomes associated with Left Ventricular ... - NIH
    Dec 24, 2021 · Black race was associated with a higher incidence of LV thrombus, (p value <0.001). Comorbidities more prevalent in the LVT group were smoking, ...Missing: male | Show results with:male
  16. [16]
    Left Ventricular Thrombus Formation After ST-Segment–Elevation ...
    Oct 19, 2015 · Left ventricular (LV) thrombus formation is a major complication after acute ST-segment–elevation myocardial infarction (STEMI).
  17. [17]
    prevention, detection and treatment modalities in the modern era
    ... DAPT could decrease the risk of LV thrombus compared with DAPT alone.7 The addition of low-dose rivaroxaban compared with no such therapy lowered the risk of LV ...Pathophysiology · Diagnostic Modalities · Transthoracic...<|control11|><|separator|>
  18. [18]
    Risk Factors for Left Ventricular Thrombus Formation in ... - Ovid
    This study suggested that elevated D-dimer levels (>444 ng/mL DDU) and reduced EF were independently associated with increased risk of LVT formation. Severe MR ...Missing: predisposing odds
  19. [19]
    Clinical predictors of left ventricular thrombus after myocardial ...
    Jan 15, 2024 · The aim of the current study is to characterize clinical predictors for LV thrombus formation, as detected by cardiac magnetic resonance imaging (CMRI).
  20. [20]
    Prediction of left ventricular thrombus after myocardial infarction
    Oct 8, 2024 · Peak high-sensitivity troponin T (ng/L), 4362.5 [2219–6956.75], 4074 ... Clinical risk score to predict early left ventricular thrombus after ST- ...
  21. [21]
    [PDF] A Rare Case of Left Ventricular Thrombus in a Normal Heart in a ...
    Aug 18, 2024 · Factor V Leiden is the most common inherited hypercoagulable state and is mostly associated with peripheral venous thrombosis and PE [7].Missing: mutations non-
  22. [22]
    Thrombophilia, Left Ventricular Dysfunction and Intracardiac ...
    Our data suggests that an underlying hypercoagulable state may be a significant risk factor for ICT in pediatric patients with left ventricular dysfunction.Missing: ischemic | Show results with:ischemic
  23. [23]
    Left ventricular wall motion score as an early predictor of left ...
    Thus, acutely assessed WMSI of >2 can readily predict subsequent dilation in patients with a first anterior infarction treated with streptokinase and is a good ...
  24. [24]
    Left ventricular thrombus formation after acute myocardial infarction
    Risk factors for the development of LV thrombus are consistently irrespective of infarct treatment and include large infarct size, severe apical asynergy (ie, ...Pathogenesis Of Lv Thrombus · Embolic Complications · Pharmacological Management
  25. [25]
    Spontaneous Echo Contrast Mistaken for Left Ventricular Thrombus ...
    SEC is a smoke-like echo density observed on echocardiograms, and is caused by increased red blood cell aggregation during low-flow states.
  26. [26]
    The role of von Willebrand factor in thrombus formation - PMC - NIH
    VWF mediates adhesion and aggregation of platelets at sites of vascular injury, processes that are critical for both haemostasis and thrombosis.
  27. [27]
    Interaction of IL-6 and TNF-α contributes to endothelial dysfunction ...
    Nov 2, 2017 · Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. ... TNF-alpha contributes to endothelial dysfunction ...
  28. [28]
    TNF-α Contributes to Endothelial Dysfunction in Ischemia ...
    Tumor necrosis factor-α (TNF-α) is an inflammatory cytokine that is expressed by macrophages and cardiac tissue early during the myocardial ischemia-reperfusion ...
  29. [29]
    Detection of left ventricular thrombus in newly diagnosed heart ...
    Nov 3, 2025 · Conclusion. 11% of patients were found to have LVT on CMR. Patients with ischemic cardiomyopathy, significantly reduced LVEF, and a dilated LV, ...
  30. [30]
    A General Shear-Dependent Model for Thrombus Formation - PMC
    Jan 17, 2017 · Modeling the transport, activation, and adhesion of platelets is crucial in predicting thrombus formation and growth following a thrombotic ...
  31. [31]
    Fibrinogen as a Cardiovascular Risk Factor: A Meta-Analysis and ...
    Jun 15, 1993 · Fibrinogen can be considered a major cardiovascular risk factor. Future studies of cardiovascular morbidity and death should include this variable.
  32. [32]
    Elevated factor VIII in a patient with acute coronary syndrome
    Various studies have established a causal association between elevated factor VIII and venous thrombosis; some studies also suggest a relation with arterial ...
  33. [33]
    PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1): A KEY FACTOR ...
    High circulating levels of PAI-1 have shown to significantly predict the onset of myocardial infarction[191]. Moreover, an acute increase in plasma PAI-1 ...
  34. [34]
    Left ventricular thrombus formation after acute myocardial infarction
    Conditions that increase the risk of systemic embolisation in patients with LV thrombus are: (1) severe congestive heart failure, (2) diffuse LV dilatation and ...
  35. [35]
    Novel Role of Platelets in Mediating Inflammatory Responses and ...
    Platelets accumulate within the infarcted myocardium, contributing to regional inflammation, ventricular remodeling, and rupture.
  36. [36]
    Left Ventricular Thrombosis in Ischemic and Non-Ischemic ... - NIH
    Feb 27, 2025 · In patients with HCM, both fibrinopeptide A and thrombin-antithrombin III complex levels are elevated [49]. Platelets show morphometric and ...
  37. [37]
    Blood Coagulation Disorders in Heart Failure: From Basic Science ...
    ... leading problem in patients with HF, HF is associated with substantial coagulation disorders. ... Does heart failure confer a hypercoagulable state? Virchow's ...Review Article · Coagulation Disorders In... · Anticoagulation For Heart...
  38. [38]
    The Association between Coagulation and Atrial Fibrillation - PMC
    Jan 25, 2024 · Elevated levels of coagulation factors are associated with both existing and newly diagnosed cases of atrial fibrillation (AF).
  39. [39]
    Crosslink between atrial fibrillation and cancer - Cardio-Oncology
    Aug 7, 2024 · Cancer-related hypercoagulability may lead AF patients to thrombus development with a related fivefold risk of thromboembolism [4, 59].
  40. [40]
    LV Thrombus After Acute MI - American College of Cardiology
    May 15, 2018 · The 2013 ACCF/AHA STEMI guidelines advise that it is reasonable to add OAC to dual antiplatelet therapy among patients with STEMI and ...Missing: absence | Show results with:absence
  41. [41]
    Challenges in management of left ventricular thrombus - PMC - NIH
    Left ventricular thrombus (LVT) complicates both ischemic and non-ischemic cardiomyopathies and is a potential cause of thromboembolic complications such as ...Missing: underlying | Show results with:underlying
  42. [42]
    A Rare Case of Left Ventricular Thrombus in a Normal Heart in ... - NIH
    Aug 18, 2024 · Left ventricular thrombus (LVT) is mostly associated with ... palpitations, and occasional chest pain not associated with activity ...
  43. [43]
    Working Backwards: Splenic Infarcts from Left Ventricular Thrombus
    Working Backwards: Splenic Infarcts from Left Ventricular Thrombus. Emmanuel ... DISCUSSION. Splenic infarction, a rare cause of abdominal pain, is more ...
  44. [44]
    Clinical profile and midterm prognosis of left ventricular thrombus in ...
    Feb 25, 2021 · Our main finding is that 1 year rate of events is sizable despite anticoagulant treatment (15% for embolic event and 5% for CV mortality). Of ...
  45. [45]
    Cardiac Imaging for Assessment of Left Ventricular Thrombus
    ### Summary of Missed LV Thrombi and Detection Challenges
  46. [46]
    Transthoracic echocardiography for the diagnosis of left ventricular ...
    The sensitivity of TTE for detecting left ventricular thrombosis ranges between 92% and 95%, with specificity of 86% to 88% [17].
  47. [47]
    Use of Transthoracic Echocardiogram to Detect Left Ventricular ...
    Jul 17, 2020 · Transthoracic echocardiography (TTE) and transesophageal echocardiography are used to detect LVT in patients with heart disease.
  48. [48]
    Cardiac CT in the diagnosis and follow-up of left ventricular thrombus
    Jul 7, 2025 · Cardiac CTA should be considered as a valuable adjunctive imaging modality in the management of complex ischemic cardiomyopathy complicated by ...
  49. [49]
    Detection of Left Ventricular Thrombus Using Cardiac Computed ...
    Left ventricular thrombus is best assessed using venous phase gated cardiac CT and can be achieved at a low radiation dose.
  50. [50]
    Left ventricular thrombus routine screening with contrast ...
    Aug 5, 2024 · One common complication of anterior STEMI is LV apical akinesia, leading to blood stasis and subsequent thrombus formation. This often occurs ...
  51. [51]
    Cardiac Imaging for Assessment of Left Ventricular Thrombus
    Sep 22, 2009 · Echo studies have generally defined thrombus as a mass within the LV cavity with margins distinct from ventricular endocardium and ...
  52. [52]
    Shape and Mobility of a Left Ventricular Thrombus Are Predictors of ...
    Left ventricular (LV) apical thrombi are usually present with LV dilatation, and oral anticoagulants reduce embolic risk in these patients.
  53. [53]
    Left Ventricular Thrombi: Insights from Cardiac Magnetic Resonance ...
    May 12, 2021 · CMR criteria for diagnosing LV thrombus were characterized as a non-enhancing mass within the LV cavity with distinct margins from the ...
  54. [54]
    Left ventricular thrombus attenuation characterization in ... - PubMed
    Results: Mean (±SD) CT attenuation of all left ventricular thrombi in 31 patients was 43.2 ± 15.3 HU (range, 25-80 HU).Missing: pseudotumor | Show results with:pseudotumor
  55. [55]
    Left ventricular apical diseases | Insights into Imaging - SpringerOpen
    Apr 18, 2011 · Hypertrophic cardiomyopathy (HCM) is a primary and genetic myocardial disease characterised by a hypertrophied, non-dilated LV in the absence of ...Apical Aneurysm And... · Apical Hypertrophic... · Tako-Tsubo Cardiomyopathy
  56. [56]
    Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus ... - JACC
    Jul 24, 2025 · We conducted an open-label, noninferiority, randomized controlled trial involving patients with acute LVT diagnosed during initial MI ...
  57. [57]
    Apixaban Is Not Inferior to Warfarin for Post-MI Left Ventricular ...
    Jan 27, 2023 · Apixaban was associated with 95% relative success in LVT resolution at 3 months vs warfarin (P <.036 for noninferiority). At 6 months, 23 ...<|separator|>
  58. [58]
    What's the optimal duration of anticoagulation in patients with left ...
    Guidelines and expert consensus recommend anticoagulation for 3-6 months with cessation of anticoagulation if interval imaging demonstrates thrombus resolution.
  59. [59]
    Direct Oral Anticoagulant Use for Left Ventricular Thrombus Treatment
    Mar 29, 2024 · Warfarin is the agent of choice for LVT treatment with a therapeutic INR range of 2 to 3. This is based off the availability of clinical data ...
  60. [60]
    Meta-Analysis of the Safety and Efficacy of Direct Oral ... - MDPI
    May 30, 2024 · Our meta-analysis demonstrates that that DOACs are comparable to warfarin in terms of efficacy (LVT resolution) and are associated with a ...2.3. Outcome Measures And... · 3. Results · 3.1. Efficacy Outcomes
  61. [61]
    Complicated Massive Left Ventricular Thrombus and Surgical ... - NIH
    Oct 4, 2022 · Surgical thrombectomy can be performed in patients with mobile and protruding thrombi. In such cases surgery should be performed immediately due ...
  62. [62]
    Management of left ventricular thrombus: a narrative review
    LVT is associated with higher risk of cardiovascular events and death, and evidence suggests anticoagulation therapy for at least 3 months reduces this risk.
  63. [63]
    Surgical removal of multiple left ventricular thrombi with video ...
    In general, a mobile or protuberant thrombus is the most important risk factor for LV thrombus embolization,1 and LV thrombus size is rarely detected as a risk ...Missing: shape | Show results with:shape
  64. [64]
    Dor procedure for left ventricular reconstruction. Ten-year clinical ...
    The Dor procedure is a reproducible surgical option for treatment of postinfarction left ventricular aneurysm. Early and long-term results are good in terms of ...Abstract · Introduction · Material and methods · Results
  65. [65]
    Postmyocardial Infarction Ventricular Aneurysm - JACC
    May 6, 2024 · Figure 9 Dor ... Time trends of ventricular reconstruction and outcomes among patients with left ventricular thrombus and aneurysms.<|control11|><|separator|>
  66. [66]
    Advances in Surgical Treatments of Left Ventricular Aneurysms - PMC
    Aug 16, 2024 · The operation was conducted as follows: after cutting the aneurysm lengthwise and clearing the thrombus, the ventricular wall was removed ...
  67. [67]
    Transfemoral Retrograde Transcatheter Mechanical Thrombectomy ...
    Oct 22, 2025 · LV thrombus remains a clinically significant and under-recognized source of embolic complications in patients with LV dysfunction. •.
  68. [68]
    Robotic transmitral resection of floating left ventricular thrombus - PMC
    Apr 24, 2025 · The primary treatment for confirmed LV thrombus is anticoagulation, with thrombolysis and surgical thrombectomy being alternative options that ...
  69. [69]
    Prophylactic Anticoagulation to Prevent Left Ventricular Thrombus ...
    Apr 15, 2024 · Clinical practice guidelines from the American Heart Association recommend consideration of prophylactic anticoagulation to prevent left ...
  70. [70]
    Lifestyle Modification in Secondary Prevention - PubMed Central - NIH
    Increasing evidence suggests that a heart-healthy diet reduces cardiovascular risk not only by favorably modifying lipids, blood pressure, body weight, and ...
  71. [71]
    Lifestyle Changes to Prevent a Heart Attack
    Jan 2, 2025 · Aim for a healthy weight · Good nutrition · Controlling calorie intake · Being physically active.Missing: remodeling thrombus
  72. [72]
    Echocardiographic Algorithm for Post-Myocardial Infarction LV ...
    Aug 9, 2025 · Cardiac magnetic resonance (CMR) is considered the gold standard for detecting LV thrombi due to its excellent sensitivity (88%) and specificity ...
  73. [73]
    https://www.cureus.com/articles/407729-beta-blockers-in-heart-failure-with-reduced-ejection-fraction-a-systematic-review-of-randomized-controlled-trials
  74. [74]
    2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
    Apr 1, 2022 · Even if symptoms or LVEF improve, long-term treatment with beta blockers and use of target doses should be maintained to reduce the risk of ...
  75. [75]
    Beta-Blockers in Heart Failure With Reduced Ejection Fraction
    Aug 29, 2025 · Beta-blockers demonstrated significant reductions in all-cause mortality and heart failure hospitalizations in chronic HFrEF patients. In ...
  76. [76]
    Comparative Effectiveness of Cardiac Resynchronization Therapy ...
    Jun 13, 2016 · Cardiac resynchronization therapy with defibrillator (CRT-D) improves survival and prevents hospitalizations in patients with symptomatic heart ...
  77. [77]
    Overview of devices in advanced heart failure
    Mar 22, 2017 · Implantable cardioverter defibrillators and cardiac resynchronisation therapy play an important role in the management of patients with advanced heart failure.
  78. [78]
    2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and ... - JACC
    Nov 30, 2023 · The 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation provides recommendations to guide clinicians.
  79. [79]
    Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy
    Cardiac resynchronization therapy (CRT) has emerged as an important therapeutic option for selected HF patients with LV dysfunction and ventricular dyssynchrony ...
  80. [80]
    Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 ...
    Patients on statins at higher risk for but without pre-existing type 2 diabetes should undergo periodic screening for diabetes with fasting glucose and HbA1c, ...Missing: stabilization LVT
  81. [81]
    Atorvastatin Improves Left Ventricular Systolic Function and Serum ...
    Moreover, statins might retard the progression of myocardial dysfunction in HF by promoting plaque stabilization and reducing the progress of CAD. We ...
  82. [82]
    Personalized management of dyslipidemias in patients with ...
    Nov 28, 2022 · found that patients with best adherence to statin therapy showed a significant reduction in risk of ischemic heart disease (IHD) by 18%, CVD by ...
  83. [83]
    Comparative effectiveness and safety of DOACs vs. VKAs in ...
    Mar 1, 2024 · In summary, the current meta-analysis supports the use of DOACs for the treatment of LVT. However, more robust data from large randomized ...
  84. [84]
    Intracardiac Thrombosis: Diagnosis, Symptoms, and More - Healthline
    Mar 8, 2023 · Left ventricular thrombus is often treated with a drug called warfarin for at least 3 to 6 months. According to this 2021 studyTrusted Source , ...
  85. [85]
    Left Ventricular Thrombus and Subsequent Thromboembolism in ...
    Peripheral embolism occurred in 5 patients (17.9%) vs 13 patients (11.2%) of those with and without LV thrombi, respectively (p = 0.35).
  86. [86]
    Renal Infarction and Decreased Splenic Perfusion Secondary to a ...
    Jul 2, 2021 · Computed Tomography (CT) confirmed an apical left ventricular thrombus and showed decreased perfusion to the spleen and ischemia/infarction of ...Missing: peripheral mesenteric
  87. [87]
    The Challenge of Managing Left Ventricular Thrombus
    Sep 15, 2022 · The Statement makes 8 practical management suggestions (summarized graphically in Figure 5) for patients at risk for or with LV thrombus, outlined here.Missing: global variations incidence
  88. [88]
    Long-Term Embolic Outcomes After Detection of Left Ventricular ...
    Nov 11, 2019 · LV thrombus detected by LGE CMR is associated with a 4-fold higher long-term incidence of embolism compared with matched non-LV thrombus patients.
  89. [89]
    Clinical characteristics, treatment and long-term outcomes of ...
    Excluding patients who presented with complications, in-hospital, 1-year and 5-year mortality were 8.5% (7/97), 17.5% (17/97), and 26.8% (26/97), respectively.
  90. [90]
    Clinical characteristics and prognosis of patients with left ventricular ...
    Sep 7, 2022 · Left ventricular thrombus (LVT) is a serious complication in patients with left ventricular dysfunction and is associated with poor outcomes.
  91. [91]
    Clinical Outcome After Left Ventricular Thrombus Resolution
    Apr 17, 2023 · LVT recurrence after LVT resolution is common, especially in those with an LV aneurysm, and is associated with a higher embolic risk.
  92. [92]
    [PDF] Clinical phenotypes and outcomes of patients with left ventricular ...
    17 The size of the thrombus was measured in millimeters, considering its maximum diameter from any angle. Left ventricular ejection fraction was calculated ...
  93. [93]
    Resolution of left ventricular thrombus assessed by echocardiography
    Jul 31, 2025 · Resolution of left ventricular thrombus assessed by echocardiography: insights from a contemporary multicentre prospective registry · Authors.<|separator|>
  94. [94]
    Direct oral anticoagulants (DOAC) versus vitamin K antagonist in left ...
    Nov 24, 2023 · DOAC use for LVT showed better thrombus resolution and reduced risk of bleeding and stroke compared to VKA. Likewise, DOAC use was associated with lower ...